GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Mar 20, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-repurchase, stock-buyback
TL;DR
GSK bought back some of its own stock today via Citigroup.
AI Summary
On March 20, 2025, GSK plc announced that it has purchased a number of its own ordinary shares through its corporate stockbroker, Citigroup Global Markets Limited. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This is a routine disclosure of share repurchases, which is common for publicly traded companies and does not indicate any unusual risk.
Key Players & Entities
- GSK plc (company) — The company making the share repurchase.
- Citigroup Global Markets Limited (company) — The corporate stockbroker acting on behalf of GSK plc for the share repurchase.
- March 20, 2025 (date) — The date of the announcement and the transactions.
FAQ
What specific number of GSK plc ordinary shares were purchased?
The filing states that GSK plc purchased 'the following number of the Company's ordinary shares' but does not specify the exact quantity in the provided text.
What was the total dollar amount spent on the share repurchases?
The filing does not disclose the total dollar amount spent on the share repurchases.
Who acted as GSK plc's corporate stockbroker for these transactions?
Citigroup Global Markets Limited acted as GSK plc's corporate stockbroker.
On what date did GSK plc announce these share repurchases?
GSK plc announced these share repurchases on March 20, 2025.
What is the par value of GSK plc's ordinary shares?
The ordinary shares of GSK plc have a par value of 31¼ pence each.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 20, 2025 regarding GSK plc (GLAXF).